Current Report Filing (8-k)
April 08 2019 - 4:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
April 2, 2019
Date of Report (Date of earliest event reported)
AEVI GENOMIC MEDICINE, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
1-35112
|
98-0217544
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
435 Devon Park Drive, Suite 715
Wayne, Pennsylvania 19087
(Address of principal executive offices,
zip code)
(610) 254-4201
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 3.01. Notice of Delisting
or Failure to Satisfy a Continued Listing, Rule or Standard; Transfer of Listing.
On April 2, 2019, Aevi Genomic Medicine, Inc. (the “Company”)
received a notification from the NASDAQ Stock Market (“NASDAQ”) stating that the Company no longer complies with the
minimum stockholders’ equity requirement under NASDAQ Listing Rule 5450(b)(1)(A) for continued listing on The NASDAQ Global
Market because the Company’s stockholder’s equity, as reported in the Company’s Annual Report on Form 10-K for
the year ended December 31, 2018, has fallen below $10 million. The notification also indicates that the Company does not meet
the alternative compliance standards set forth in NASDAQ Listing Rule 5450(b).
Under applicable NASDAQ rules, the Company has 45 calendar days
from the date of the notification letter, or until May 17, 2019, to submit a plan to regain compliance. If the Company’s
plan is accepted, NASDAQ may grant the Company an extension of up to 180 calendar days from the date of the notification to provide
evidence of compliance. Alternatively, the Company may consider applying to transfer the Company’s common stock to The NASDAQ
Capital Market, which has a minimum stockholders’ equity requirement of $2.5 million, provided that the Company meets the
continued listing requirements of The NASDAQ Capital Market at such time.
The Company will consider all available options to regain compliance
with the continued listing standards of NASDAQ.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AEVI GENOMIC MEDICINE, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Michael F. Cola
|
|
|
|
Name: Michael F. Cola
|
|
|
|
Title: President and Chief Executive Officer
|
|
Date: April 8, 2019
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Sep 2023 to Sep 2024